Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study

• Jorge E. Cortes,
• Jeff H. Lipton,
• Vamsi Kota,
• Fausto Castagnetti,
• Sarit Assouline,
• Tim H. Brümmendorf,
• Eric Leip,
• Andrea Viqueira,
• Carlo Gambacorti-Passerini

Affiliations

Jorge E. Cortes

Georgia Cancer Center, Augusta, GA

Jeff H. Lipton

Princess Margaret Cancer Centre, Toronto, ON

Vamsi Kota

Georgia Cancer Center, Augusta, GA

Fausto Castagnetti

Istituto di Ematologia “Seràgnoli”, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna

Sarit Assouline

McGill University, Montreal, QC

Tim H. Brümmendorf

Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University Hospital, Aachen, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD)

Eric Leip

Pfizer Inc, Cambridge, MA

Andrea Viqueira

Pfizer SLU, Madrid

Carlo Gambacorti-Passerini

University of Milano-Bicocca, Monza